PREDICT · EVALUATION OF LIPID LEVELS PRIOR AND DURING GESTATION AND ASSOCIATION WITH ADVERSE PREGNANCY OUTCOMES AND SUBSEQUENT DEVELOPMENT OF TRUE DYSLIPIDEMIA. POPULATION BASED STUDY.

Background:The metabolic syndrome is characterized by a group of metabolic risk factors such as obesity (mainly abdominal obesity), atherogenic dyslipidemia (high triglycerides, low HDL cholesterol), elevated blood pressure and dysglycemia. Several components of the metabolic syndrome (glucose intolerance and elevated blood pressure) are known risk factors for development of pregnancy complications.The objective of the proposed study is to characterize the metabolic syndrome and especially disturbance of lipid homeostasis over the reproductive cycle of women life starting from preconception assessment, through gestational period and during three years following birth.Study cohortThe study population of 600 women undergoing pre-pregnancy routine assessment will be enrolled. At the baseline detailed medical history assessment, physical examination and blood tests will be performed. This cohort will undergo the similar assessment at weeks 12, 24 and at the delivery.This cohort will be assessed again annually for 3 years following the delivery (medical history; physical examination and blood tests).Hypotheses:1) Elevated triglycerides levels (≥150mg/dL) and/or low levels of high density lipoprotein (<50mg/dL) assessed prior to conception are associated with preeclampsia/ eclampsia, and/or gestational diabetes mellitus.2) Elevated triglycerides levels (>75 percentile for the appropriate gestational age) and/or low levels of high density lipoprotein (<25 percentile) assessed during the gestation are associated with the adverse pregnancy outcomes.3) Women with elevated triglycerides levels and low levels of high density lipoprotein during pregnancy have higher rates of metabolic syndrome at 3 years after the delivery.Importance:Our study will help to identify additional risk factor for adverse pregnancy outcomes and identify a risk group for development of insulin resistance associated pathologies such as dyslipidemia and metabolic syndrome.